A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
- Registration Number
- NCT05469100
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 9 days, excluding screening.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 37
For all participants:
- Body mass index (BMI) ≥ 18.0 and ≤ 40.0 kilograms per meter squared (kg/m²) and had a minimum weight of at least 50 kg at screening
- Have normal blood pressure, pulse rate, electrocardiogram (ECG), and blood and urine laboratory test results that are acceptable for the study
- Female of non childbearing potential: must have undergone sterilization procedures at least 6 months prior to the Screening
- Males who are capable of fathering a child must agree to use contraception from the time of the dose administration through 6 months after the last dose
For renal participants:
-
Participant has stable renal disease status and function at least 1 month prior to LOXO-292 administration.
-
Participant is not currently or has not previously being on hemodialysis
-
Baseline estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease (MDRD) equation at screening as follows:
- Severe Renal Impairment (RI): < 30 milliliter per minute (mL/min)/1.73m²
- Moderate RI: ≥ 30 and < 60 mL/min/1.73m²
- Mild RI: ≥ 60 and < 90 mL/min/1.73m²
The MDRD equation is as follows (for females multiply result by 0.742, if African American multiply result by 1.212):
eGFR = 175 x [serum creatinine in milligrams per deciliter (mg/dL) measured with a standardized assay]^-1.154 x (Age)^-0.203
For renal participants:
- Has rapidly fluctuating renal function, as determined by historical measurements; or has demonstrated or suspected renal artery stenosis. Rapidly fluctuating renal function is defined as creatinine clearance or eGFR that differs by more than 20% within at least 3 months of the screening creatinine clearance or eGFR. If historical measurements are not available, then the 2 screening measurements will be used to demonstrate stability.
- Participants who have had a renal transplant, a nephrectomy, or participants with a known history of nephrotic syndrome.
- Participants who have required new medication for renal disease within 30 days prior to Check-in
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort 1: Selpercatinib (Healthy participants) Selpercatinib Single oral dose of Selpercatinib administered in a fasted state to participants with normal renal function. Cohort 2: Selpercatinib (Participants with mild renal impairment) Selpercatinib Single oral dose of Selpercatinib administered in a fasted state to participants with mild renal impairment. Cohort 4: Selpercatinib (Participants with severe renal impairment) Selpercatinib Single oral dose of Selpercatinib administered in a fasted state to participants with severe renal impairment and not on dialysis. Cohort 3: Selpercatinib (Participants with moderate renal impairment) Selpercatinib Single oral dose of Selpercatinib administered in a fasted state to participants with moderate renal impairment.
- Primary Outcome Measures
Name Time Method PK: Area under the concentration-time curve, from time 0 extrapolated to infinity (AUC0-inf) of Selpercatinib 0 to up to 168 hours post-dose PK: AUC0-inf of Selpercatinib
PK: Time to reach Cmax (Tmax) of Selpercatinib 0 to up to 168 hours post-dose PK: Tmax of Selpercatinib
PK: Apparent first order terminal elimination rate constant (Kel) of Selpercatinib 0 to up to 168 hours post-dose PK: Kel of Selpercatinib
PK: Apparent first-order terminal elimination half-life (t½) of Selpercatinib 0 to up to 168 hours post-dose PK: t½ of Selpercatinib
PK: Total amount of drug excreted in the urine over the entire period of sample collection (Ae) of Selpercatinib 0 to up to 168 hours post-dose PK: Ae of Selpercatinib
PK: Fraction of drug excretion during each collection interval (Fe) of Selpercatinib 0 to up to 168 hours post-dose PK: Fe of Selpercatinib
Pharmacokinetics (PK): Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) of Selpercatinib 0 to up to 168 hours post-dose PK: AUC0-t of Selpercatinib
PK: Area under the concentration-time curve, from time 0 to Hour 24 (AUC0-24) of Selpercatinib 0 to up to 168 hours post-dose PK: AUC0-24 of Selpercatinib
PK: Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F) of Selpercatinib 0 to up to 168 hours post-dose PK: Vz/F of Selpercatinib
PK: Apparent total plasma clearance after oral (extravascular) administration (CL/F) of Selpercatinib 0 to up to 168 hours post-dose PK: CL/F of Selpercatinib
PK: Renal clearance (CLr) of Selpercatinib 0 to up to 168 hours post-dose PK: CLr of Selpercatinib
PK: Percent of AUC0-inf extrapolated (AUC%extrap) of Selpercatinib 0 to up to 168 hours post-dose PK: AUC%extrap of Selpercatinib
PK: Maximum observed concentration (Cmax) of Selpercatinib 0 to up to 168 hours post-dose PK: Cmax of Selpercatinib
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Orange County Research Center
🇺🇸Tustin, California, United States
Stanford Health Care, Valley Care Program
🇺🇸Pleasanton, California, United States
Anaheim Regional Center
🇺🇸Anaheim, California, United States
Riverside Clinical Research
🇺🇸Edgewater, Florida, United States
Clinical Pharmacology of Miami
🇺🇸Miami, Florida, United States
Orlando Clinical Research Center
🇺🇸Orlando, Florida, United States